Evidence map›Paper›PMID 40666482›Full record

ArticleACS medicinal chemistry letters2025

Acridone Prodrugs with Enhanced Dual-Stage Antimalarial Efficacy.

Rozalia A Dodean, Yuexin Li, Xiaowei Zhang, Amrendra Kumar, Sovitj Pou, Rolf W Winter, Katherine M Liebman, Lev N Zakharov, Diana Caridha, Michael S Madejczyk and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Rozalia A DodeanDepartment of Chemistry, Portland State University, Portland, Oregon 97201, United States.ORCID https://orcid.org/0000-0001-5002-4607
Yuexin LiDepartment of Veterans Affairs Medical Center, Portland, Oregon 97239, United States.
Xiaowei ZhangDepartment of Veterans Affairs Medical Center, Portland, Oregon 97239, United States.
Amrendra KumarDepartment of Chemistry, Portland State University, Portland, Oregon 97201, United States.
Sovitj PouDepartment of Veterans Affairs Medical Center, Portland, Oregon 97239, United States.
Rolf W WinterDepartment of Veterans Affairs Medical Center, Portland, Oregon 97239, United States.
Katherine M LiebmanDepartment of Veterans Affairs Medical Center, Portland, Oregon 97239, United States.
Lev N ZakharovCAMCOR, University of Oregon, Eugene, Oregon 97403, United States.
Diana CaridhaExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Michael S MadejczykExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Chau VuongExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Jesse DeLucaExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Geoffrey ChinExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.ORCID https://orcid.org/0009-0001-6793-3337
Karl KudybaExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Sharon McEnearneyExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Xiannu JinExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
William E DennisExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Ravi ChetreeExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Cameron BlountExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Kristina PannoneExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Hieu T DinhExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Kennedy MdakiExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Susan LeedExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Patricia J LeeExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Alison RothExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Papireddy KancharlaDepartment of Chemistry, Portland State University, Portland, Oregon 97201, United States.ORCID https://orcid.org/0000-0002-6381-1236
Jane X KellyDepartment of Chemistry, Portland State University, Portland, Oregon 97201, United States.ORCID https://orcid.org/0000-0001-8871-0207

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we present a prodrug strategy that successfully led to the development of highly potent dual-stage antimalarial acridone analogs with radical cure potential. Notably, the prodrug

Indexed as

acridonesantimalarialantiplasmodialblood-stagedual-stageliver-stagemalariaprodrugsprophylacticradical cure

Identifiers

PMID40666482
PMCPMC12257405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.